AbbVie & Gilgamesh have teamed up & signed an option-to-license agreement to develop neuroplastogens through AbbVie’s psychiatry knowledge & Gilgamesh’s research platform
As per the agreement, both companies will research & develop a portfolio of neuroplastogens. AbbVie, upon option exercise, will handle development & commercialization while Gilgamesh will obtain $65M upfront and a total of up to $1.95B as option exercise fee & milestones plus mid-single to low-double net-sales based tiered royalties
Neuroplastogens are the next-generation therapies designed for treating various psychiatric conditions, incl. mood & anxiety disorders while addressing the challenges seen with first-generation compounds
Ref: Medincell | Image: Medincell
Related News:- AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
